ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2025
High societal costs and reduced health-related quality of life in inflammatory and systemic immune disease-associated dilated cardiomyopathies.
Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundDilated cardiomyopathy (DCM) comes with an estimated societal cost of above €10,000 per patient per year and a lower quality of life (QoL). However, DCM represents a heterogeneous disease with different aetiologies that can be combined in subgroups. Insight in QoL and societal costs per DCM subgroup may guide resource allocation, research focus areas, and tailored patient management. We investigated subgroup-specific costs and QoL in patients with DCM.
methodsPatients with DCM (n = 550) were included, all phenotyped by endomyocardial biopsy and genetic testing besides routine cardiac evaluation. Patients were classified as chemotherapy-induced DCM (n = 27), genetic DCM (n = 91), inflammatory DCM (n = 53), systemic immune-mediated disease (SID)-associated DCM (n = 83), alcohol-induced DCM (n = 40), and idiopathic DCM (n = 280). QoL and societal costs were cross-sectionally evaluated using the EQ-5D-5 L and the iMTA medical and productivity cost questionnaires, sent at 8 [IQR 5; 12] years after cardiomyopathy diagnosis.
resultsCompared to other subgroups, QoL was lower for inflammatory DCM (-0.053 [-0.106; -0.003], p = 0.04), SID-associated DCM (-0.078 [-0.126; -0.031], p < 0.01), and alcohol-induced DCM (-0.079 [-0.141; -0.017], p = 0.01). Societal costs were higher for patients with inflammatory DCM (19,197€ [13,703 − 27,211]; log-transformed change + 0.862 [0.103; 1.621], p = 0.03), and SID-associated DCM (19,197€ [8,494 − 25,623]; log-transformed change + 0.804 {0.104; 1.505], p = 0.03). Healthcare costs were highest for patients with inflammatory DCM (6,198€ [4,083 − 8,626], log-transformed change + 0.614 [0.039; 1.189] p = 0.049).
conclusionPatients with DCM due to chronic myocarditis or a SID have lower QoL and higher societal costs due to higher healthcare costs, compared to patients with DCM and other etiologies. These findings may guide resource allocation, research focus areas, and tailored management such as patient education, financial counseling, and psychological support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.